Jan Astermark
101 – 150 of 179
- show: 50
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2010
-
Mark
F8 haplotype and recombinant product use in the Hemophilia Inhibitor Genetics Study (HIGS)
(
- Contribution to journal › Published meeting abstract
-
Mark
Inhibitor development: patient-determined risk factors.
(
- Contribution to journal › Article
-
Mark
Combination of FVIII and by-passing agent potentiates in vitro thrombin production in haemophilia A inhibitor plasma.
(
- Contribution to journal › Article
-
Mark
Thrombin generation in vitro in the presence of by-passing agents in siblings with severe haemophilia A.
(
- Contribution to journal › Article
-
Mark
Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report.
(
- Contribution to journal › Article
-
Mark
Physical activity for prevention of osteoporosis in patients with severe haemophilia on long-term prophylaxis.
(
- Contribution to journal › Article
-
Mark
Von Willebrands sjukdom--från biokemi till klinisk praxis.
(
- Contribution to journal › Scientific review
- 2009
-
Mark
Impact of polymorphisms of the major histocompatibility complex class II, interleukin-10, tumor necrosis factor-alpha and cytotoxic T-lymphocyte antigen-4 genes on inhibitor development in severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Thrombin generation assay: a useful routine check-up tool in the management of patients with haemophilia?
(
- Contribution to journal › Article
-
Mark
Arandomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study.
(
- Contribution to journal › Article
-
Mark
Cumulative incidence of inhibitors: it is influenced by type of replacement therapy in previously treated boys with severe haemophilia A. No
(
- Contribution to journal › Published meeting abstract
-
Mark
Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Maintenance treatment with 5-azacitidine for patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia following MDS (MDS-AML) in complete remission (CR) after induction chemotherapy
2009) 10th International Symposium on Myelodysplastic Syndromes In Leukemia Research 33(Suppl 1). p.49-50(
- Contribution to journal › Published meeting abstract
-
Mark
Genetic Factors Associated with Inhibitor Development in Hemophilia A: Initial Results From the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
(
- Contribution to journal › Published meeting abstract
-
Mark
Characterization of a Novel Aberrant Splice Site, 79bp Downstream of Exon 5 in the Human Factor 7 Gene Detected in Patients with Severe Congenital Factor VII Deficiency.
(
- Contribution to journal › Published meeting abstract
-
Mark
European curriculum for thrombosis and haemostasis.
(
- Contribution to journal › Article
- 2008
-
Mark
Value added: increasing the power to assess treatment outcome in joint haemorrhages
(
- Contribution to journal › Article
-
Mark
Thrombin generation assay: a useful tool in the management of haemophilia A patients?
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.26-26(
- Contribution to journal › Published meeting abstract
-
Mark
Maintenance Treatment with 5-Azacitidine for Patients with High Risk Myelodysplastic Syndrome (MDS) or Acute Myeloid Leukemia Following MDS (MDS-AML) in Complete Remission (CR) after Induction Chemotherapy
(
- Contribution to journal › Published meeting abstract
-
Mark
European principles of haemophilia care
(
- Contribution to journal › Article
-
Mark
From theory to practice: Applying current clinical knowledge and treatment strategies to the care of hemophilia A patients with inhibitors
(
- Contribution to journal › Scientific review
-
Mark
The importance of maintaining FVIII through levels above 1% during prophylactic treatment of hemophilia A: using license study databases to answer key medical questions
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.58-58(
- Contribution to journal › Published meeting abstract
-
Mark
New risk factors for inhibitor development
2008) XXVIIIth International Congress of the World Federation of Hemophilia, 2008 In Haemophilia 14(s2). p.43-43(
- Contribution to journal › Published meeting abstract
-
Mark
Variability of clinical manifestations of factor VII-deficiency in subjects homozygous or heterozygous for the F7 gene mutation A294V
(
- Contribution to journal › Letter
-
Mark
Inhibitor development.
(
- Contribution to journal › Article
-
Mark
Cost and outcome: comparisons of two alternative bypassing agents for persons with haemophilia A complicated by an inhibitor.
(
- Contribution to journal › Article
- 2007
-
Mark
Polymorphisms in the CTLA-4 gene and inhibitor development in patients with severe hemophilia A
(
- Contribution to journal › Article
-
Mark
Negative effect of DNA hypermethylation on the outcome of intensive chemotherapy in older patients with high-risk myelodysplastic syndromes and acute myeloid leukemia following Myelodysplastic syndrome
(
- Contribution to journal › Article
-
Mark
Impact of different inhibitor reactivities with commercial factor VIII concentrates on thrombin generation
(
- Contribution to journal › Article
-
Mark
A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor.
(
- Contribution to journal › Article
-
Mark
The APC-PCI complex concentration predicts outcome of aortic surgery.
(
- Contribution to journal › Article
-
Mark
Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
- 2006
-
Mark
Inhibitor treatment in haemophilas A and B: Summary statement for the 2006 International Consensus Conference
(
- Contribution to journal › Debate/Note/Editorial
-
Mark
Current European practice in immune tolerance induction therapy in patients with haemophilia and inhibitors.
(
- Contribution to journal › Article
-
Mark
Basic aspects of inhibitors to factors VIII and IX and the influence of non-genetic risk factors.
(
- Contribution to journal › Article
-
Mark
Why do inhibitors develop? Principles of and factors influencing the risk for inhibitor development in haemophilia.
(
- Contribution to journal › Article
-
Mark
Polymorphisms in the IL-10 but not in the IL-1{beta} and IL-4 genes are associated with inhibitor development in patients with hemophilia A.
(
- Contribution to journal › Article
-
Mark
Polymorphisms in the TNFA gene and the risk of inhibitor development in patients with hemophilia A.
(
- Contribution to journal › Article
-
Mark
Overview of inhibitors.
(
- Contribution to journal › Article
-
Mark
Overview of inhibitors
(
- Chapter in Book/Report/Conference proceeding › Paper in conference proceeding
-
Mark
Inhibitor development in hemophiliacs: The roles of genetic versus environmental factors
(
- Contribution to journal › Article
- 2005
-
Mark
Haemophilia Inhibitor Genetics Study - evaluation of a model for studies of complex diseases using linkage and association methods.
(
- Contribution to journal › Letter
-
Mark
Protein C levels can be forecasted by global haemostatic tests in critically ill patients and predict long-term survival.
(
- Contribution to journal › Article
-
Mark
The Malmö International Brother Study (MIBS). Genetic defects and inhibitor development in siblings with severe hemophilia A.
(
- Contribution to journal › Article
- 2003
-
Mark
When to start and when to stop primary prophylaxis in patients with severe haemophilia.
(
- Contribution to journal › Article
-
Mark
Monitoring the bioavailability of FEIBA with a thrombin generation assay
(
- Contribution to journal › Article
-
Mark
Consensus perspectives on prophylactic therapy for haemophilia: summary statement.
(
- Contribution to journal › Letter
-
Mark
Impact of inhibitor epitope profile on the neutralizing effect against plasma-derived and recombinant factor VIII concentrates in vitro.
(
- Contribution to journal › Article
-
Mark
Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay
(
- Contribution to journal › Article
-
Mark
Thrombosis in inherited factor VII deficiency.
(
- Contribution to journal › Article